Roche Stock Earnings Estimates Cut by Erste Group Bank

Key Points

• Erste Group Bank lowered Roche’s earnings forecasts, reducing FY2026 EPS to $3.05 from $3.14 and projecting FY2027 EPS of $3.31. The FY2026 estimate remains slightly above the $3.03 consensus.
• Analyst sentiment remains generally favorable, with Roche holding a “Moderate Buy” consensus rating and an average price target of approximately $60.
• Roche reported positive Phase III results for vamikibart and secured a potential $1.16 billion licensing deal with China’s Rona Therapeutics for an obesity-related RNAi therapy, adding potential growth opportunities.

Roche Holding AG (OTCMKTS:RHHBY - Free Report) - Analysts at Erste Group Bank cut their FY2026 earnings per share estimates for Roche in a research note issued on Thursday, October 8th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $3.05 per share for the year, down from their prior estimate of $3.14. The consensus estimate for Roche's current full-year earnings is $3.03 per share. Erste Group Bank also issued estimates for Roche's FY2027 earnings at $3.31 EPS.

Several other equities analysts have also weighed in on RHHBY. HSBC reaffirmed a "hold" rating on shares of Roche in a research note on Thursday, September 10th. Morgan Stanley raised shares of Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 target price for the company in a research report on Friday, August 7th. Royal Bank Of Canada started coverage on shares of Roche in a report on Tuesday, September 8th. They issued an "outperform" rating on the stock. Finally, Zacks Research upgraded shares of Roche from a "strong sell" rating to a "hold" rating in a report on Monday, August 24th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, Roche has a consensus rating of "Moderate Buy" and an average price target of $60.00.

Roche Price Performance

Shares of OTCMKTS:RHHBY opened at $54.10 on Tuesday. The business has a 50-day moving average of $54.90 and a two-hundred day moving average of $52.59. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.23. Roche has a 12 month low of $40.07 and a 12 month high of $60.85.

Institutional Trading of Roche

Several large investors have recently added to or reduced their stakes in the stock. Woodstock Corp acquired a new stake in Roche in the 3rd quarter valued at $245,000. GAMMA Investing LLC raised its position in Roche by 15.3% in the third quarter. GAMMA Investing LLC now owns 33,458 shares of the company's stock valued at $1,736,000 after purchasing an additional 4,443 shares during the period. Renasant Bank acquired a new position in shares of Roche during the second quarter worth about $210,000. North Star Asset Management Inc. acquired a new position in shares of Roche during the second quarter worth about $1,351,000. Finally, Puzo Michael J purchased a new stake in shares of Roche in the second quarter worth about $1,229,000.

Trending Headlines about Roche

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Roche agreed to a global licensing deal with China’s Rona Therapeutics for an ALK7-targeting RNAi therapy aimed at obesity and related metabolic diseases. The agreement could be worth up to $1.16 billion, strengthening Roche’s presence in the highly competitive obesity-drug market and adding a potential long-term growth asset. Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics
• Positive Sentiment: Roche reported positive Phase III results for vamikibart in uveitic macular edema, including sustained vision improvements, fewer retreatments and a favorable safety profile. The FDA has accepted the biologics license application, moving the drug closer to a potential U.S. launch and new revenue opportunity. Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
• Neutral Sentiment: Brokerage analysts have a consensus target price of approximately $60 for Roche, implying potential upside from recent trading levels, although target prices are not guarantees of future performance. Roche Holding AG Stock Has Consensus Target Price of $60 According to Brokerages
• Negative Sentiment: Erste Group Bank reduced its Roche EPS forecasts to $3.05 for FY2026 from $3.14 and to $3.31 for FY2027 from $3.41. Although the revised FY2026 estimate remains slightly above the $3.03 consensus, the cuts signal softer expectations for near-term earnings growth.

About Roche

Roche Holding AG is a Swiss healthcare company headquartered in Basel, Switzerland. Founded in 1896, the company operates through two core divisions: Pharmaceuticals and Diagnostics. Roche develops medicines and diagnostic technologies intended to support disease prevention, detection, diagnosis and treatment.

Roche's pharmaceutical activities focus on areas including oncology, immunology, neuroscience, ophthalmology, hematology and rare diseases. Its portfolio includes biologic and small-molecule medicines, as well as individualized healthcare approaches that use diagnostic information to help guide treatment decisions.

Through its Diagnostics division, Roche provides in vitro diagnostic systems, molecular testing, tissue-based diagnostics, diabetes-care products and laboratory solutions for healthcare providers, laboratories and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.